ABBVIE INC

AbbVie’s $12 bn senior‑note deal fuels an Apogee Therapeutics acquisition, boosts R&D and reflects robust governance and philanthropy in immunology.

AbbVie’s $8 billion bond fuels Apogee’s anti‑inflammatory pipeline, gains UBRELVY reimbursement in Canada and expands BOTOX to masseter muscle—balancing debt, regulatory wins and aesthetic growth.

AbbVie Q2 2026 review: revenue up 5.7 %, earnings grow 18%, R&D stays lean, and analysts upgrade targets while patent expirations and biosimilar risk loom.

AbbVie beats earnings thanks to a surge in Skyrizi sales, but a costly Apogee acquisition forces a profit forecast cut, sparking investor worry about short‑term earnings drag.

AbbVie’s Q2 2026 earnings beat on Skyrizi and Rinvoq growth, yet its $5.3 billion Apogee deal trims EPS – a nuanced look at gains, integration costs and future upside.

AbbVie’s Q2 earnings reveal a pharma pivot: Humira sales dip yet oncology pipeline and Allergan integration drive growth, with macro and biosimilar risks highlighted.

First‑quarter 2026: Piramal Pharma shows steady revenue growth, higher EBITDA, and strong FDA compliance, positioning it for continued success in CDMO, generics, and consumer‑healthcare markets.

AbbVie’s newest biologic launches—Product A for ulcerative colitis and Product B for triple‑negative breast cancer—boost its pipeline and signal strong upside amid a booming antibody‑therapeutics market.

AbbVie’s upcoming earnings reveal how a new acquisition fuels R&D growth, regulatory strategy, and future cash flow amid Fed‑driven market volatility.

AbbVie’s $3.8 bn acquisition of Atai Beckley gives it a Breakthrough‑Therapy‑designated fast‑acting nasal spray for treatment‑resistant depression and social anxiety, expanding its CNS portfolio into a multi‑billion‑dollar psychedelic market.